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SUMMARY – Tigecycline susceptibility testing (TST) presents a tremendous challenge for clin-
ical microbiologists. Previous studies have shown that the Epsilometer test (E-test) and Vitek 2 auto-
mated system signifi cantly overestimate the minimum inhibitory concentrations for tigecycline resis-
tance compared to the broth microdilution method (BMM). Th is leads to very major errors or false 
susceptibility (i.e. the isolate is called susceptible when it is actually resistant). Th e aim of this study 
was to compare E-test against BMM for TST in carbapenem-resistant and carbapenem-susceptible 
Acinetobacter (A.) baumannii and to analyze changes in tigecycline susceptibility between two time 
periods (2009-2012 and 2013-2014), with BMM as the gold standard. Using the EUCAST criteria, 
the rate of resistance to tigecycline for the OXA-23 MBL-positive, OXA-23 MBL-negative and 
carbapenemase-negative strains for BMM was 54.5% (6/11), 29.4% (5/17) and 2.7% (1/37), respec-
tively; the OXA-24/40 and OXA-58 producing organisms did not exhibit any resistance. With E-test, 
all OXA-23 MBL-positive organisms (11/11), 23.5% (4/17) of OXA-23 MBL-negative, and 4.1% of 
OXA-24/40 (3/74) strains displayed tigecycline resistance; there were no resistant strains among the 
OXA-58 and carbapenemase-negative isolates. Resistance emerged in the bacterial isolates from 2013 
to 2014. Although tigecycline does not display cross-resistance, the highest rates of resistant A. bau-
mannii isolates were observed among those producing VIM MBL, regardless of the testing method. 
Th ese fi ndings suggest that the commercial E-test does not provide reliable results for TST of A. 
baumannii. Further confi rmation with the dilution method should be recommended, particularly in 
cases of serious infections.
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Introduction
Acquired carbapenem resistance is an emerging 
problem in Acinetobacter (A.) baumannii due to the 
production of acquired carbapenemases of class A 
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(KPC)1, class B metallo--lactamases (MBLs) of the 
IMP, VIM, SIM and NDM families2-6, and class D 
carbapenem-hydrolyzing oxacillinases (OXA-23-, 
OXA-40-, OXA-58-, OXA-143- and OXA-238-like) 
[CHDL]7-12. Carbapenem-resistant A. baumannii 
(CRAB) isolates have been reported worldwide13. 
Carbapenem resistance in A. baumannii is a growing 
concern in Croatia and neighboring countries14-20. In 
addition to the hospital setting, CRAB has also been 
identifi ed in environmental samples in Croatia21-23. 
CRAB isolates are frequently associated with serious 
infections such as ventilator-associated pneumonia, 
septicemia and urinary tract infections, specifi cally in 
intensive care units24-25. Th ey are often a cause of 
wound, skin and soft tissue infections, and secondary 
meningitis25.
Tigecycline and colistin are often last-resort anti-
biotics for the treatment of infections associated with 
carbapenemase-producing organisms. Tigecycline, the 
fi rst semisynthetic glycocycline, is a minocycline de-
rivative that overcomes major tetracycline resistance 
mechanisms26. However, tigecycline resistance has also 
emerged27. Th erapeutic decisions often rely on appro-
priate susceptibility testing. Th e issue is that tigecy-
cline susceptibility testing (TST) remains a major 
challenge for clinical microbiologists. Th us far, there 
are no clear guidelines established by either the Clini-
cal and Laboratory Standards Institute (CLSI)28 or 
the European Committee on Antimicrobial Suscepti-
bility Testing (EUCAST) for TST of A. baumannii.
In most studies, the breakpoints applied for En-
terobacteriaecae include the susceptibility breakpoint 
of ≤1 mg/L and the resistance breakpoint of ≥4 mg/L. 
Disk-diff usion test is not appropriate for susceptibility 
testing for tigecycline. Previous studies have shown 
that the Epsilometer test (E-test) and Vitek 2 system 
signifi cantly overestimate the minimum inhibitory 
concentrations (MICs) of tigecycline compared to the 
broth microdilution method (BMM), leading to very 
major errors (i.e. false susceptibility)29,30. Th e aim of 
this study was to compare two diff erent methods for 
TST (E-test and BMM) in carbapenem-resistant and 
carbapenem-susceptible A. baumannii and to analyze 
dynamic changes in tigecycline susceptibility between 
two collection periods (2009-2012 and 2013-2014). 
Th e fi rst period (2009-2012) was chosen because it 
was in that time-frame that the fi rst carbapenem-re-
sistant isolates were identifi ed in both countries (Re-
public of Croatia and Republic of Bosnia and Herze-
govina). During the second period (2013-2014), it was 
observed that tigecycline resistance had emerged and 
this prompted further evaluation of its prevalence and 
TST problems. In this study, BMM was considered as 
the gold standard for TST.
Material and Methods
Bacteria
During the two collection periods, a total of 154 
bacterial isolates were obtained. Within the scope of 
this multicentre study, the isolates from 2009 to 2012 
were retrieved from 13 diff erent hospital centers in 
Croatia and from the Mostar General Hospital in 
Bosnia and Herzegovina. Th e isolates from the second 
period (2013-2014) were collected in two centers in 
Croatia, the Pula General Hospital and Godan Nurs-
ing Home in Zagreb. Bacterial strains were identifi ed 
by conventional biochemical testing (matrix-assisted 
laser desorption/ionization time-of-fl ight mass spec-
trometry, MALDI-TOF MS) and verifi ed by poly-
merase chain reaction (PCR) for bla
OXA-51
 gene. Mo-
lecular characterization of carbapenem resistance was 
performed as in previous studies16-20.
Antibiotic susceptibility testing
Th e isolates were classifi ed as multidrug-resistant 
(MDR), extensively drug-resistant (XDR) or pan-
drug-resistant (PDR) according to Magiorakos et al.31. 
Susceptibility to tigecycline was determined by BMM 
and E-test. Antimicrobial susceptibility was confi rmed 
by BMM in Mueller-Hinton broth in 96-well mi-
crotiter plates according to the CLSI guidelines28. 
Pseudomonas aeruginosa ATCC 27853 and A. bauman-
nii ATCC 19606 were used as quality control strains. 
Since CLSI does not have interpretative criteria for 
TST for A. baumannii, resistance rates were calculated 
according to the EUCAST criteria for Enterobacteri-
aceae32 or the U. S. Food and Drug Administration 
(FDA) criteria33, with resistance breakpoints of >2 or 
≥8 mg/L, respectively.
Interpretation of data
Categorical agreement (CA) was defi ned as the 
percentage of isolates recorded in the same susceptibil-
ity category by BMM and E-test as defi ned previously 
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by Zarkotou et al.30. Category discrepancies were 
grouped as follows: (i) very major errors (VME) in 
cases where BMM indicated resistance and the com-
parative method indicated susceptibility; (ii) major er-
rors (ME) when an isolate was categorized as suscep-
tible by BMM and resistant by the comparative meth-
od; and (iii) minor errors (mE) when there was one 
interpretation category diff erence between BMM and 
the comparative method. Essential agreement (EA) 
was considered to be the percentage of MICs within 1 
doubling dilution of the MIC determined by BMM30.
Results
Isolates with acquired oxacillinases were labeled 
MDR or XDR, as described by Magiorakos et al.31. 
When a MIC breakpoint of >2 mg/L was applied ac-
cording to the EUCAST criteria for defi ning resis-
tance to tigecycline32, the rate of resistance for BMM 
was 54.5% (6/11) for OXA-23 MBL-positive, 29.4% 
(5/17) for OXA-23 MBL-negative, and 2.7% (1/37) 
for carbapenemase-negative strains. Th e OXA-24/40- 
and OXA-58-producing organisms did not exhibit 
any resistance. In contrast, in E-test, all OXA-23 
MBL-positive organisms (11/11), 23.5% (4/17) of 
OXA-23 MBL-negative, and 4.1% (3/74) of OXA-
24/40 strains showed resistance to tigecycline, as dis-
played in Table 1. Th ere were no resistant strains 
among the OXA-58 and carbapenemase-negative iso-
lates. Using the FDA criteria with a resistance break-
point of ≥8 mg/L33, no resistant isolates were detected, 
regardless of the testing method. Th e strains collected 
from 2009 to 2012 exhibited full susceptibility to tige-
cycline. However, resistance emerged in those obtained 
during the 2013-2014 period.
Th e MIC
90
 ranged from 2 mg/L (OXA-24/40 and 
OXA-58) to 8 mg/L (OXA-23 MBL positive) with 
BMM and from 2 mg/L (OXA-24/40, OXA-23 
MBL-negative and OXA-58) to 4 mg/L (OXA-23 
MBL positive) in E-test. Th e MIC
50
 varied between 1 
and 4 mg/L with BMM and between 2 and 4 mg/L in 
E-test (Table 1).
When BMM was considered the gold standard for 
antibiotic susceptibility testing, 5 (45.5%) MBL-posi-
tive and 8 (10.7%) OXA-24/40 isolates were noted as 
resistant instead of susceptible, demonstrating a ME 
of E-test (Table 2). VME (i.e. resistant strain being 
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(2.7%) of the carbapenemase-negative strains (Table 
2). Th e rates of mEs were 58.7%, 45.5%, 33.3%, 29.4% 
and 27.0% for OXA-24/40, MBL, OXA-58, OXA-23 
MBL-negative and carbapenemase-negative isolates, 
respectively. Th e highest rate of EA was observed for 
OXA-24/40 (94.7%), followed by OXA-58 (93.3%), 
OXA-23 MBL-negative (88.2%), carbapenemase-
negative (86.5%), and OXA-23 MBL-positive (81.8%) 
strains (Table 2). Th e CA was highest in OXA-23 
MBL-negative strains (70.6%) and lowest in car-
bapenemase-negative strains (27.0%).
Discussion
Although tigecycline does not display cross-resis-
tance, the highest rates of resistance were observed 
among the VIM MBL-producing isolates, regardless 
of the testing method. Emergence of tigecycline resis-
tance was detected for isolates from the 2013-2014 
collection period, whereas those from 2009 to 2012 
were fully susceptible. Tigecycline testing by E-test 
produced higher MICs, yielding ME in 45.5% of 
MBL-positive isolates, while VME was detected in 
only one carbapenemase-negative strain. Th e rates of 
EA of approximately 80% to 90% and CA of 60% to 
70% were similar to those found by Zarkotou et al.30. 
Th ere are no published studies so far on the accuracy of 
particular tests in isolates with diff erent carbapenem-
resistance mechanisms.
According to the results of this study, E-test did 
not provide reliable results. Hence, these should be 
substantiated by the dilution method. Th is is especially 
important in case of severe infections. Although con-
sidered the gold standard, BMM is laborious, time-
consuming and requires educated staff . In addition, 
these fi ndings confi rm the elevated MICs of tigecy-
cline by E-test compared to BMM, as previously de-
tailed by other authors. However, the discrepancies 
between these two methods were less pronounced in 
our study than in the published literature, where the 
MICs of BMM were overestimated two- to three-fold 
by the E-test30.
Like the present study, false-resistant outcomes 
(i.e. MEs) have also been reported in previous stud-
ies29,30. Th e explanation provided by Marchaim et al. is 
that E-test detects heteroresistance that is very com-
mon in A. baumannii and cannot be identifi ed by broth 
methods34. Th e phenomenon of increased MICs by E-
test is unique only for A. baumannii and has not been 
detected in Enterobacteriaceae34. Th e resistance to ti-
gecycline was predominantly associated with VIM-
producing organisms. Nonetheless, a limitation of this 
study was that the MBL-positive isolates from the 
nursing home in Zagreb belonged to a single clone. It 
is diffi  cult to explain the reason for cross-resistance in 
MBL-positive isolates since MBLs are encoded on 
mobile genetic elements, whereas tigecycline resis-
tance is due to hyperexpression of effl  ux pumps. A 
possible explanation may be that the carbapenemase-
producing organisms have a greater ability to acquire 
other resistance traits as well.
Conclusions
Given that BMM is time-consuming and necessi-
tates educated staff , it is not routinely performed in 
most laboratories. Instead, either the E-test or Vitek 2 
is preferred. Clinicians and laboratory personnel alike 
should be made aware of the discordances between E-
test and other microbial sensitivity testing methods, 
particularly in critically ill patients. Th erefore, accord-
ing to our results, BMM should be recommended for 
TST of A. baumannii.
Table 2. Rate of errors in E-test compared to broth microdilution method
Type of oxacillinase % of VME % of ME % of mE % of EA % of CA
OXA-23 MBL- positive 0/11 (0%) 5/11 (45.5%) 5/11 (45.5%) 9/11 (81.8%) 6/11 (54.5%)
OXA-23 MBL- negative 0/17 (0%) 0/17 (0%) 5/17 (29.4%) 15/17 (88.2%) 12/17 (70.6%)
OXA-24/40 0/75 (0%) 8/75 (10.7%) 44/75 (58.7%) 71/75 (94.7%) 44/75 (58.7%)
OXA-58 0/15 (0%) 0/15 (0%) 5/15 (33.3%) 14/15 (93.3%) 10/15 (66.7%)
Carbapenemase negative 1/37 (2.7%) 0/37 (0%) 10/37 (27.0%) 32/37 (86.5%) 10/37 (27.0%)
VME = very major error; ME = major error; mE = minor error; EA = essential agreement; CA = categorical agreement
Branka Bedenić et al. Tigecycline susceptibility testing
622 Acta Clin Croat, Vol. 57, No. 4, 2018
References
 1. Robledo IE, Aquino EE, Santé MI, Santana JL, Otero DM, 
León CF, et al. Detection of KPC in Acinetobacter spp. in Puer-
to Rico. Antimicrob Agents Chemother. 2010;54:1354-7, 
https://dx.doi.org/10.1128/AAC.00899-09
 2. Cornaglia G, Riccio ML, Mazzariol A, Lauretti L, Fontana R, 
Rossolini GM. Appearance of IMP-1 metallo-beta-lactamase 
in Europe. Lancet. 1999;353:899-900.
 3. Amudhan MS, Sekar U, Kamalanathan A, Balaraman S. 
Bla(IMP) and bla(VIM) mediated carbapenem resistance in 
Pseudomonas and Acinetobacter species in India. J Infect Dev 
Ctries. 2012;6:757-62, https://dx.doi.org/10.3855/jidc.2268
 4. El-Ageery SM, Al-Hazmi SS. Microbiology and molecular 
detection of VIM-1 metallo beta lactamase-producing Acineto-
bacter baumannii. Eur Rev Med Pharmacol Sci. 2014;18:
965-70.
 5. Lee K, Yum JH, Yong D, Lee HM, Kim HD, Docquier JD, et 
al. Novel acquired metallo-beta-lactamase gene, bla(SIM-1), in 
a class 1 integron from Acinetobacter baumannii clinical isolates 
from Korea. Antimicrob Agents Chemother. 2005;49:4485-91, 
https://dx.doi.org/10.1128/AAC.49.11.4485-4491.2005
 6. Hrabák J, Stolbová M, Studentová V, Fridrichová M, Chu-
dáčková E, Zemlickova H. NDM-1 producing Acinetobacter 
baumannii isolated from a patient repatriated to the Czech Re-
public from Egypt, July 2011. Euro Surveill. 2012;17.
 7. Brown S, Amyes S. OXA (beta)-lactamases in Acinetobacter: the 
story so far. J Antimicrob Chemother. 2006;57:1-3, https://
dx.doi.org/10.1093/jac/dki425
 8. Stoeva T, Higgins PG, Bojkova K, Seifert H. Clonal spread of 
carbapenem-resistant OXA-23-positive Acinetobacter bauman-
nii in a Bulgarian university hospital. Clin Microbiol Infect. 
2008;14:723-7, 
 https://dx.doi.org/10.1111/j.1469-0691.2008.02018.x
 9. Bou G, Oliver A, Martínez-Beltrán J. OXA-24, a novel class D 
beta-lactamase with carbapenemase activity in an Acinetobacter 
baumannii clinical strain. Antimicrob Agents Chemother. 
2000;44:1556-61.
10. Pournaras S, Markogiannakis A, Ikonomidis A, Kondyli L, 
Bethimouti K, Maniatis AN, et al. Outbreak of multiple clones 
of imipenem-resistant Acinetobacter baumannii isolates express-
ing OXA-58 carbapenemase in an intensive care unit. J Anti-
microb Chemother. 2006;57:557-61, 
 https://dx.doi.org/10.1093/jac/dkl004
11. Higgins PG, Poirel L, Lehmann M, Nordmann P, Seifert H. 
OXA-143, a novel carbapenem-hydrolyzing class D beta-lacta-
mase in Acinetobacter baumannii. Antimicrob Agents Che-
mother. 2009;53:5035-8, 
 https://dx.doi.org/10.1128/AAC.00856-09
12. Higgins PG, Pérez-Llarena FJ, Zander E, Fernández A, Bou 
G, Seifert H. OXA-235, a novel class D -lactamase involved 
in resistance to carbapenems in Acinetobacter baumannii. Anti-
microb Agents Chemother. 2013;57:2121-6, https://dx.doi.
org/10.1128/AAC.02413-12
13. Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter 
baumannii: mechanisms and epidemiology. Clin Microbiol In-
fect. 2006;12:826-36, 
 https://dx.doi.org/10.1111/j.1469-0691.2006.01456.x
14. Goic-Barisic I, Bedenic B, Tonkic M, Katic S, Kalenic S, Pun-
da-Polic V. First report of molecular characterization of car-
bapenem-resistant Acinetobacter baumannii in diff erent inten-
sive care units in University Hospital Split, Croatia. J Che-
mother. 2007;19:462-4, 
 https://dx.doi.org/10.1179/joc.2007.19.4.462
15. Goic-Barisic I, Bedenic B, Tonkic M, Novak A, Katic S, Ka-
lenic S, et al. Occurrence of OXA-107 and ISAba1 in carbape-
nem-resistant isolates of Acinetobacter baumannii from Croatia. 
J Clin Microbiol. 2009;47:3348-9, 
 https://dx.doi.org/10.1128/JCM.02394-08
16. Franolić-Kukina I, Bedenić B, Budimir A, Herljević Z, Vraneš 
J, Higgins PG. Clonal spread of carbapenem-resistant OXA-
-72-positive Acinetobacter baumannii in a Croatian university 
hospital. Int J Infect Dis. 2011;15:e706-9, 
 https://dx.doi.org/10.1016/j.ijid.2011.05.016
17. Vranić-Ladavac M, Bedenić B, Minandri F, Ištok M, Bošnjak Z, 
Frančula-Zaninović S, et al. Carbapenem resistance and acquired 
class D beta-lactamases in Acinetobacter baumannii from Croatia 
2009-2010. Eur J Clin Microbiol Infect Dis. 2014;33:471-8, 
https://dx.doi.org/10.1007/s10096-013-1991-9
18. Bedenić B, Beader N, Godič-Torkar K, Vranić-Ladavac M, 
Luxner J, Veir Z, et al. Nursing home as a reservoir of carbape-
nem-resistant Acinetobacter baumannii. Microb Drug Resist. 
2015;21:270-8, https://dx.doi.org/10.1089/mdr.2014.0157
19. Ladavac R, Bedenić B, Vranić-Ladavac M, Barišić N, Karčić N, 
Pompe K, et al. Emergence of diff erent Acinetobacter baumannii 
clones in a Croatian hospital and correlation with antibiotic 
susceptibility. J Glob Antimicrob Resist. 2017;10:213-8, 
https://dx.doi.org/10.1016/j.jgar.2017.07.001
20. Petrović T, Uzunović S, Barišić I, Luxner J, Grisold A, Zarfel 
G, et al. Arrival of carbapenem-hydrolyzing-oxacillinases in 
Acinetobacter baumannii in Bosnia and Herzegovina. Infect 
Genet Evol. 2018;58:192-8, https://dx.doi.org/10.1016/j.
meegid.2017.12.021
21. Hrenovic J, Durn G, Goic-Barisic I, Kovacic A. Occurrence of 
an environmental Acinetobacter baumannii strain similar to a 
clinical isolate in paleosol from Croatia. Appl Environ Micro-
biol. 2014;80:2860-6, 
 https://dx.doi.org/10.1128/AEM.00312-14
22. Hrenovic J, Durn G, Music MS, Dekic S, Troskot-Corbic T, 
Skoric D. Extensively and multi drug-resistant Acinetobacter 
baumannii recovered from technosol at a dump site in Croatia. 
Sci Total Environ. 2017;607-608:1049-55, https://dx.doi.
org/10.1016/j.scitotenv.2017.07.108
23. Hrenovic J, Goic-Barisic I, Kazazic S, Kovacic A, Ganjto M, 
Tonkic M. Carbapenem-resistant isolates of Acinetobacter bau-
mannii in a municipal wastewater treatment plant, Croatia, 
2014. Euro Surveill. 2016:14;21, 
 https://dx.doi.org/10.2807/1560-7917.ES.2016.21.15.30195
Branka Bedenić et al. Tigecycline susceptibility testing
Acta Clin Croat, Vol. 57, No. 4, 2018 623
24. Mammina C, Palma DM, Bonura C, Aleo A, Fasciana T, So-
dano C, et al. Epidemiology and clonality of carbapenem-resis-
tant Acinetobacter baumannii from an intensive care unit in Pal-
ermo, Italy. BMC Res Notes. 2012;5:365, https://dx.doi.
org/10.1186/1756-0500-5-365
25. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: 
emergence of a successful pathogen. Clin Microbiol Rev. 
2008;21:538-82, https://dx.doi.org/10.1128/CMR.00058-07
26. Cai Y, Wang R, Liang B, Bai N, Liu Y. Systematic review and 
meta-analysis of the eff ectiveness and safety of tigecycline for 
treatment of infectious disease. Antimicrob Agents Chemother. 
2011;55:1162-72, https://dx.doi.org/10.1128/AAC.01402-10
27. Al-Sweih NA, Al-Hubail MA, Rotimi VO. Emergence of ti-
gecycline and colistin resistance in Acinetobacter species isolated 
from patients in Kuwait hospitals. J Chemother. 2011;23:13-6, 
https://dx.doi.org/10.1179/joc.2011.23.1.13
28. Clinical and Laboratory Standards Institute. Performance 
standards for antimicrobial susceptibility testing; Twenty-
fourth informational supplement. CLSI document M100-S24. 
Wayne, PA: Clinical and Laboratory Standards Institute; 2014.
29. Grandesso S, Sapino B, Amici G, Mazzucato D. Solinas M, 
Gion M. Are E-test and Vitek 2 good choices for tigecycline 
susceptibility testing when comparing broth microdilution for 
MDR and XDR Acinetobacter baumannii? New Microbiol 
2014;37:503-8.
30. Zarkotou O, Pournaras S, Altouvas G, Pitiriga V, Tziraki M, 
Mamali V, et al. Comparative evaluation of tigecycline suscep-
tibility testing method for expanded-spectrum cephalosporin- 
and carbapenem-resistant gram-negative pathogens. J Clin 
Microbiol. 2012;50:3747-50, 
 https://dx.doi.org/10.1128/JCM.02037-12
31. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas 
ME, Giske CG, et al. Multidrug-resistant, extensively drug-
resistant and pandrug-resistant bacteria: an international ex-
pert proposal for interim standard defi nitions for acquired 
 resistance. Clin Microbiol Infect. 2012;18:268-81, 
 https://dx.doi.org/10.1111/j.1469-0691.2011.03570.x
32. European Committee on Antimicrobial Susceptibility Testing 
(EUCAST). 2012. Breakpoint tables for interpretation of 
MICs and zone diameters. Version 2.0, valid from 2012-01-01. 
http://www.eucast.org/clinical_breakpoints/
33. U. S. Food and Drug Administration. Recognized antibacterial 
susceptibility test interpretative criteria; 2018, accessed 12 
March 2018.
34. Marchaim D, Pogue JM, Tzuman O, Hayakawa K, Lephart 
PR, Salimnia H, et al. Major variation in MICs of tigecycline 




USPOREDBA DVIJU RAZLIČITIH METODA ZA TESTIRANJE OSJETLJIVOSTI NA TIGECIKLIN 
U ACINETOBACTER BAUMANNII
B. Bedenić , G. Cavrić, M. Vranić-Ladavac, N. Barišić, N. Karčić, T. Tot, A. Presečki-Stanko, 
A. Lukić-Grlić, S. Frančula-Zaninović i K.B. Sreter
Testiranje osjetljivosti na tigeciklin (TST) je velik izazov za kliničke mikrobiologe. Prethodna istraživanja su pokazala da 
E-test i Vitek 2 daju veće vrijednosti minimalne inhibitorne koncentracije tigeciklina u odnosu na dilucijsku metodu, što 
uzrokuje vrlo veliku grešku (engl. very major error, što znači da je rezistentan izolat proglašen osjetljivim). Cilj istraživanja bio 
je usporediti dvije metode za testiranje osjetljivosti na tigeciklin (E-test i bujonska dilucijska metoda) u karbapenem osjetlj-
vim i karbapenem rezistentnim izolatima Acinetobacter (A.) baumannii s različitim tipovima karbapenem-hidrolizirajućih 
oksacilinazama i analizirati promjenu u stopama osjetljivosti na tigeciklin u dva razdoblja istraživanja (2009.-2012. i 2013.-
2014.). Dilucija u bujonu je bila referentna metoda. Testiranje osjetljivosti na tigeciklin je provedeno E-testom i bujonskom 
mikrodilucijskom metodom. Prema kriterijima EUCAST-a stopa rezistencije bila je 54,5% (6/11) za OXA-23 MBL-pozi-
tivne sojeve, 29,4% (5/17) za OXA-23 MBL-negativne sojeve i 2,7% (1/37) za karbapenemaza-negativne sojeve uz bujonsku 
mikrodilucijsku metodu. OXA-24/40 i OXA-58 producirajući sojevi nisu iskazivali rezistenciju. E-testom su svi OXA-23 
MBL pozitivni organizmi (11/11), 23,5% (4/17) OXA-23 MBL negativnih i 4,1% OXA-24/40 (3/74) pokazivali rezisten-
ciju na tigeciklin. Svi OXA-58 pozitivni i karbapenemaza-negativni sojevi su bili osjetljivi na tigeciklin u E-testu. Rezisten-
cija na tigeciklin se pojavila u razdoblju od 2013. do 2014. godine. Iako tigeciklin ne pokazuje križnu rezistenciju s drugim 
antibioticima najviše stope rezistencije su zapažene među VIM-pozitivnim izolatima bez obzira na metodu testiranja. Prema 
rezultatima našega istraživanja komercijalni E-test ne daje pouzdane rezultate TST u A. baumannii. Potrebna je potvrda 
 dilucijskom metodom, osobito kod teških infekcija.
Ključne riječi: Tigeciklin; Disk difuzija, antimikrobni testovi; Mikrobi, testovi osjetljivosti; Acinetobacter baumannii; Lijekovi, 
rezistencija, bakterijska
